In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78.

Slides:



Advertisements
Similar presentations
Y OUNG I NNOVATORS 2009 Prostate-Specific Membrane Antigen (PSMA)-Targeted Imaging, Diagnosis, and Therapy of Prostate Cancer using a PSMA inhibitor as.
Advertisements

The biodistribution and pharmacokinetics of [68Ga]Ga-1 in the orthotopic xenograft mice using µPET dynamic acquisitions. The biodistribution and pharmacokinetics.
H31m1-PDL1 cells form progressively growing tumors in WT mice.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.
Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.
Bioluminescence imaging facilitates detection of tumor growth and metastasis in mouse orthotopic xenograft model. Bioluminescence imaging facilitates detection.
Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies in athymic nude mice bearing the s.c. Biodistribution of the muNR-LU-10 and huNR-LU-13 antibodies.
L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.
TFAP2A knockdown inhibits tumor growth in vivo.
Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.
Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model in vivo. Antitumor activity of HER2-lytic hybrid peptide in tumor xenograft model.
In vivo homing of intravenously injected CSNRDARRC peptide to bladder tumor in rats. In vivo homing of intravenously injected CSNRDARRC peptide to bladder.
coTCRcys-transduced T cells control tumor growth in vivo.
In vitro binding and specificity of OTL78.
Effects of DPM treatment on tumor volume, tumor mass, and pulmonary metastasis at experimental end point. Effects of DPM treatment on tumor volume, tumor.
Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.
Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c
Matriptase-2 inhibited breast tumor development in vivo.
Vascular staining in CWR22R xenograft tumors.
VEGF expression in neoplastic and normal prostate tissue.
MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.
Active AR signaling in enzalutamide-resistant xenograft tumors.
EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo. EMT gene expression patterns of M-Wnt and E-Wnt cells in vitro and in vivo.
The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.
PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.
Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.
Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.
In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. In vivo tumorigenicity of MKN-1 cells with sustained suppression of HDAC2. A,
ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,
In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.
Uptake of TEX by DCs in vivo.
ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.
Determination of MTD for romidepsin and pralatrexate and associated antitumor activity. Determination of MTD for romidepsin and pralatrexate and associated.
Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.
In vivo bioluminescence imaging of primary tumors and tumor metastasis
Ex vivo imaging of lymph nodes with tumor metastasis using a bioluminescence imaging system. Ex vivo imaging of lymph nodes with tumor metastasis using.
Systemic reovirus treatment targets disseminated human myeloma in vivo
Whole body gamma camera images of 111In-CHX-A”-DTPA hu3S193 diabody in BALB/c mice bearing s.c. Whole body gamma camera images of 111In-CHX-A”-DTPA hu3S193.
Whole body gamma camera images of 111In-CHX-A”-DTPA hu3S193 F(ab′)2 in BALB/c mice bearing s.c. Whole body gamma camera images of 111In-CHX-A”-DTPA hu3S193.
A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.
PK profile of OTL78. PK profile of OTL78. A, Representative time-dependent whole-body fluorescence images over white light images of a mouse bearing 22Rv1.
Effect of NO and eNOS on prostate cancer cell growth.
Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.
Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
A, TSG-6 staining in human prostate.
RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.
Biodistributions 24 hours after injection of different 177Lu-chCE7F(ab′)2 conjugates ( MBq, 13 μg) in tumor-bearing nude mice: effect of the number.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
Axial 1advanced technology laboratory animal scanner PET images of [11C]DCMC in (A) MCF-7 and (B) PC-3 tumor-bearing mice. Axial 1advanced technology laboratory.
TAE-684 effectively inhibits the growth of H3122 in vivo.
Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.
Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.
Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.
In vivo tumor targeting and biodistribution of radiolabeled anti-CEA Fab-H-2Kb/ova conjugates. In vivo tumor targeting and biodistribution of radiolabeled.
A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.
Representative biodistribution pattern of 111In-CMD-193.
BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.
Effects of W. chinensis extract on androgen activity and growth of prostate cancer cells. Effects of W. chinensis extract on androgen activity and growth.
Mutation of the Smad3 linker phosphorylation sites in 4T1 cells reduces putative stem cell population and tumor initiating frequency of cells from the.
Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor cells after weekly CAR+ T-cell treatment for 4 wks. Bioluminescent imaging of NALM-6(GFP-FFLuc) tumor.
Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv) localization in tumor-bearing mice and BsAb half-life in mouse blood. Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)
Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.
W. chinensis extract attenuates tumor growth of 103E (a subline of CWR22Rv1) engrafted in the prostate of nude mice. W. chinensis extract attenuates tumor.
Detection of microcalcifications in 4T1 mammary tumors and human breast tumor tissue. Detection of microcalcifications in 4T1 mammary tumors and human.
Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.
MET activation confers resistance to cetuximab (Cmab) or panitumumab (Pmab) in colon cancer cell lines in vitro and in vivo. MET activation confers resistance.
Presentation transcript:

In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. In vivo efficacy and specificity of OTL78 in orthotopic and subcutaneous tumor models using the AMI image system. Representative fluorescence images from the AMI image system showing mice bearing (A) 22Rv1 subcutaneous (n = 3 mice/group), (B) LNCaP subcutaneous (n = 3 mice/group), and (C) 22Rv1 orthotopic (n = 5 mice/group) tumors 2 hours after administering 10 nmol/L of OTL78. Tissue biodistribution analysis of the same mice with (D) 22Rv1, (E) LNCaP, and (F) 22Rv1 tumors at 2 hours after injection. Note: *Primary tumor is in the prostate in G; K, kidneys; PT, primary tumor; SC, secondary tumor; and SV, seminal vesicle. Sumith A. Kularatne et al. Clin Cancer Res 2019;25:177-187 ©2019 by American Association for Cancer Research